Hypertension and atrial fibrillation: risks reshaping cardiovascular prevention

Hypertension and atrial fibrillation (AF) are closely interlinked, representing two of the most prevalent cardiovascular conditions with shared pathophysiological mechanisms and compounding clinical consequences. Up to 80% of patients with AF have a history of elevated blood pressure, while hypertension significantly raises the lifetime risk of developing AF. Structural remodeling of the heart—including left ventricular hypertrophy and atrial enlargement—underpins this association, accompanied by neurohormonal activation, endothelial dysfunction, and chronic inflammation.

AF not only complicates blood pressure control but amplifies the risk of stroke, heart failure, and cardiovascular mortality. Blood pressure variability, particularly nocturnal surges and morning spikes, has emerged as an independent predictor of incident AF, highlighting the importance of ambulatory blood pressure monitoring. Importantly, effective hypertension control—targeting systolic levels below 130 mmHg—can reduce AF incidence and recurrence. Renin-angiotensin system blockers, particularly angiotensin receptor blockers (ARBs), show added benefit in AF prevention among high-risk hypertensive individuals.

For patients with coexisting AF and hypertension, integrated management strategies are critical. These include rhythm and rate control tailored to individual symptoms and comorbidities, anticoagulation to prevent thromboembolic events, and strict adherence to blood pressure targets. Emerging research suggests that upstream therapies such as mineralocorticoid receptor antagonists or sodium-glucose cotransporter 2 inhibitors (SGLT2i) may offer protective cardiovascular effects, although definitive AF prevention data remain limited.

This evolving understanding calls for a proactive approach in cardiovascular care, where recognizing the bidirectional link between AF and hypertension can enable earlier interventions and more effective long-term outcomes.